NCCN announces the availability of NCCN Guidelines for Patients®: Caring for Adolescents and Young Adults, a patient-friendly translation of the NCCN Guidelines® focused on people diagnosed with cancer between the ages of 15 and 39. FORT WASHIN...
Biopharmaceuticals, Devices, Oncology
National Comprehensive Cancer Network, NCCN, young adults with cancer

NEW YORK & PETACH TIKVAH, Israel--(Healthcare Sales & Marketing Network)--BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr. Alon Natanson as it...
Regenerative Medicine, Neurology, Personnel
BrainStorm Cell Therapeutics, stem cell

BLOOMINGTON, Ind.--(Healthcare Sales & Marketing Network)--The only Food and Drug Administration (FDA) approved ureteral access sheath that has two options for placement is now available in the United States. The Flexor® Parallel™ Rapid Release™ Ureter...
Devices, Urology, Product Launch
Cook Medical, Flexor Parallel, Ureteral Access Sheath

94% Procedural Technical Success Rate; Significantly Reduced Procedure Times and Time to Hemostasis IRVINE, Calif., Jan. 28, 2013 -- (Healthcare Sales & Marketing Network) -- Endologix, Inc. (ELGX), developer and marketer of innovative treatments for ao...
Devices, Interventional
Endologix, PEVAR , endovascular, abdominal aortic aneurysm, ProGlide

WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Augmenix, Inc., an innovative medical technology company focused on utilizing hydrogel technology in the fields of tissue marking and radiation oncology, today announced that it has received 510(k) cl...
Devices, Oncology, Radiology, FDA
Augmenix, TraceIT, Tissue Marker, absorbable tissue marker, hydrogel

Clinicians Can Fully Assess and Optimize Patient Outcomes Before the Valve is Secured in Place, Creating a More Certain and Reproducible Clinical Result SANTA ROSA, Calif.--(Healthcare Sales & Marketing Network)--Direct Flow Medical®, Inc., a trans...
Devices, Interventional Cardiology, Regulatory
Direct Flow Medical, transcatheter heart valve, aortic regurgitation

The primary endpoint - to show a survival advantage in the intention to treat (ITT) population - was not reached. In a subgroup analysis, patients with low/normal baseline IL-6 and expected anti-superantigen antibody levels demonstrated proof of concept...
Biopharmaceuticals, Oncology
Active Biotech, ANYARA, Tumor Targeting Superantigen, renal cell cancer

Genzyme Also Reports Very Encouraging Early Launch Indicators for AUBAGIO® (teriflunomide) in U.S. CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Dr...
Biopharmaceuticals, Neurology, FDA
Genzyme, Sanofi, LEMTRADA, alemtuzumab, multiple sclerosis